CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

CHAMPIONS ONCOLOGY, INC.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026

$4.69−0.01 (-0.21%)

Close on Oct 19, 2026

Market cap: $65.18M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jul 31, 2026

Champions Oncology reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Champions Oncology's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Champions Oncology's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Sep 11, 2015
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CSBR.

Revenue growth6.7% · median -51.5%

Operating margin-1.7% · median -319.6%

Net margin-1.8% · median -395.2%

Company	Revenue	Growth
DNA	$111.86M	-46.8%
CSBR	$60.66M	+6.7%
RXRX	$54.86M	-15.1%
STRO	$45.70M	-56.3%
CGEN	–	–
BDTX	$0	-100.0%

Company

Next earnings (est.): Dec 14, 2026, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: April 30
Employees: 214
Held by institutions: 42.4%
Auditor: EISNERAMPER LLP
SEC CIK: 771856

Advertisement
300 × 250